AtomVie Global Radiopharma Inc. ("AtomVie") today announced the successful closing of its Series A financing with Avego Management, LLC ("Avego"), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Organization) for the development, manufacturing, and global distribution of radiopharmaceuticals and has received a financing commitment of at least $40 million.
AtomVie
is a spinout from the CPDC (Centre for Probe Development and
Commercialization), and within CPDC, the CMO business unit, now AtomVie, served
as the GMP manufacturer and supplier of finished-dose therapeutic
radiopharmaceuticals for the past seven years. AtomVie will be expanding its
current clinical GMP manufacturing capacity of radiopharmaceutical products to
include commercial stage production through the construction of a new
purpose-built state of the art facility designed to accommodate multiple
isotopes. Moreover, AtomVie complements its manufacturing and logistics
expertise with a high-standard quality management system and global regulatory
support.
To
read more please visit:
AtomVie
Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego
Source:
CISION